The patent enhances Aeris Therapeutics’ intellectual property portfolio in the area of methods of treating emphysema.
AeriSeal System is designed to non-surgically reduce lung volume in order to improve lung function and quality of life in patients with advanced emphysema.
Aeris said that with AeriSeal System therapy, a physician uses a bronchoscope to direct treatment to the most damaged areas of the patient’s lungs, which delivers a proprietary Foam Sealant that seals and collapses the treatment area, thereby reducing lung volume.
Aeris Therapeutics recently began commercialisation of its product, the AeriSeal System, in Europe.
